Transaction overview
Arcutis Biotherapeutics (NASDAQ:ARQT) Senior Vice President and Chief Financial Officer Latha Vairavan reported the disposition of 1,320 shares of common stock on February 2, 2026, according to a Form 4 filed with the Securities and Exchange Commission. The shares were sold at prices between $24.745 and $25.68 for a combined proceeds amounting to $33,657.
The filing indicates the sale was completed to meet tax withholding obligations arising from the vesting of restricted stock units that were granted on January 12, 2024. After the sale, Vairavan’s direct ownership in Arcutis stands at 63,607 shares.
Market position and valuation
At the time of the transaction, Arcutis shares were trading at $26.08. According to the cited InvestingPro data in the filing, the stock has returned 97.88% over the past 12 months and 70.18% over the last six months. The company is described as having a market capitalization of $3.18 billion and gross profit margins of 89.96%, and is trading close to its InvestingPro Fair Value.
Near-term corporate calendar
Investors are reminded that Arcutis is scheduled to announce its next quarterly earnings on February 25, 2026.
Recent operational and clinical developments
Arcutis reported positive topline data from its Phase 2 INTEGUMENT-INFANT study of ZORYVE cream in infants with atopic dermatitis, with a 75% improvement on the Eczema Area and Severity Index observed in 58% of trial participants. This clinical readout was disclosed alongside several commercial and corporate updates.
The company and Kowa Pharmaceuticals America mutually agreed to terminate their promotion agreement for ZORYVE. As a result, Arcutis has assumed responsibility for sales activities for the product.
Board-level changes were also announced: Amit Munshi has joined Arcutis’s Board of Directors following the retirement of founder Bhaskar Chaudhuri.
On the commercial outlook, Mizuho raised its price target for Arcutis to $37.00 and maintained an Outperform rating, citing stronger-than-expected prescription trends for ZORYVE.
Regulatory milestone
The U.S. Food and Drug Administration has accepted Arcutis’s application seeking to expand the indication for ZORYVE to treat plaque psoriasis in younger children and has set a target action date for June 2026. If approved, ZORYVE cream would become the first topical PDE4 inhibitor for plaque psoriasis approved for children as young as two years old, according to the company’s disclosure.
Contextual note
The sale by the CFO was tied to the mechanics of RSU vesting and tax withholding rather than an open-market portfolio reallocation described in the filing. The company’s recent clinical, commercial, governance and regulatory items were disclosed contemporaneously and may be of interest to investors monitoring Arcutis’s near-term execution and approval pathway.